Artelo Biosciences, Inc. (ARTL)

1.4400 -0.0600 (-4.00%) 收市：04:00PM EDT

Artelo Biosciences, Inc.

505 Lomas Santa Fe
Suite 160
Solana Beach, CA 92075
United States
858 925 7049
https://www.artelobio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 6

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Gregory D. Gorgas M.B.A.	President, CEO, CFO, Treasurer, Secretary & Director	742.45k	無	1963
Dr. Andrew Yates Ph.D.	Senior VP & Chief Scientific Officer	無	無	無
Dr. Steven D. Reich	Chief Medical Officer	無	無	1946
Mr. Jason H. Baybutt	Senior Vice President of Finance	無	無	1972

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

公司管治

截至 無 止，Artelo Biosciences, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。